Vancea A, Serban O, Fodor D
"Iuliu Hațieganu" University of Medicine and Pharmacy, 2 Internal Medicine Department, Cluj-Napoca, Romania.
Acta Endocrinol (Buchar). 2021 Oct-Dec;17(4):509-516. doi: 10.4183/aeb.2021.509.
Recent studies suggest that osteopontin (OPN) could be used as an early marker for the diagnosis of bone disorders. Considering the contradictory opinions in the literature, the objective of this systematic review is to analyse the current information regarding the relationship between OPN and bone mineral density (BMD), which represents an important process in the development of osteoporosis. We performed a literature search of clinical trials using the PubMed database, published between 1999-2020, and identified 7 studies that were eligible for analysis. The eligibility criteria were based on studies that analysed the relationship between osteopontin and bone mineral density on human subjects. Conclusion: serum OPN levels might be used as a biomarker of the early diagnosis of osteoporosis in postmenopausal women, with or without osteoporotic vertebral fractures.
近期研究表明，骨桥蛋白（OPN）可作为诊断骨疾病的早期标志物。鉴于文献中存在相互矛盾的观点，本系统评价的目的是分析有关OPN与骨密度（BMD）之间关系的现有信息，骨密度是骨质疏松症发展过程中的一个重要指标。我们使用PubMed数据库对1999年至2020年间发表的临床试验进行了文献检索，确定了7项符合分析条件的研究。纳入标准基于分析骨桥蛋白与人类受试者骨密度之间关系的研究。结论：血清OPN水平可作为绝经后女性骨质疏松症早期诊断的生物标志物，无论其是否发生骨质疏松性椎体骨折。
